AKBA
Price
$1.85
Change
+$0.02 (+1.09%)
Updated
Dec 23, 03:53 PM (EDT)
79 days until earnings call
BEAM
Price
$28.69
Change
-$0.32 (-1.10%)
Updated
Dec 23, 04:59 PM (EDT)
71 days until earnings call
Ad is loading...

AKBA vs BEAM

Header iconAKBA vs BEAM Comparison
Open Charts AKBA vs BEAMBanner chart's image
Akebia Therapeutics
Price$1.85
Change+$0.02 (+1.09%)
Volume$4.5K
CapitalizationN/A
Beam Therapeutics
Price$28.69
Change-$0.32 (-1.10%)
Volume$12.37K
CapitalizationN/A
AKBA vs BEAM Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. BEAM commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and BEAM is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (AKBA: $1.83 vs. BEAM: $29.01)
Brand notoriety: AKBA and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 253% vs. BEAM: 220%
Market capitalization -- AKBA: $400.36M vs. BEAM: $2.4B
AKBA [@Biotechnology] is valued at $400.36M. BEAM’s [@Biotechnology] market capitalization is $2.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 5 TA indicator(s) are bullish while BEAM’s TA Score has 3 bullish TA indicator(s).

  • AKBA’s TA Score: 5 bullish, 4 bearish.
  • BEAM’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, AKBA is a better buy in the short-term than BEAM.

Price Growth

AKBA (@Biotechnology) experienced а -1.08% price change this week, while BEAM (@Biotechnology) price change was +3.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.12%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was +3.33%.

Reported Earning Dates

AKBA is expected to report earnings on Mar 12, 2025.

BEAM is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.12% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.41B) has a higher market cap than AKBA($400M). AKBA YTD gains are higher at: 47.581 vs. BEAM (6.576). AKBA has higher annual earnings (EBITDA): 4.3M vs. BEAM (-160.83M). BEAM has more cash in the bank: 926M vs. AKBA (34M). AKBA has less debt than BEAM: AKBA (48.6M) vs BEAM (162M). BEAM has higher revenues than AKBA: BEAM (350M) vs AKBA (170M).
AKBABEAMAKBA / BEAM
Capitalization400M2.41B17%
EBITDA4.3M-160.83M-3%
Gain YTD47.5816.576724%
P/E RatioN/AN/A-
Revenue170M350M49%
Total Cash34M926M4%
Total Debt48.6M162M30%
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBABEAM
RSI
ODDS (%)
Bearish Trend 4 days ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
80%
Aroon
ODDS (%)
Bullish Trend 4 days ago
88%
N/A
View a ticker or compare two or three
Ad is loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSEAX16.570.19
+1.16%
Russell Inv US Strategic Equity A
BIAFX41.460.47
+1.15%
Brown Advisory Flexible Equity Inv
LMISX24.570.26
+1.07%
Franklin U.S. Large Cap Equity IS
VBIAX50.330.38
+0.76%
Vanguard Balanced Index Adm
MSEIX66.740.17
+0.26%
AMG Veritas Asia Pacific I

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+2.23%
ABOS - AKBA
42%
Loosely correlated
+2.78%
KOD - AKBA
41%
Loosely correlated
-0.35%
ABCL - AKBA
41%
Loosely correlated
+5.17%
BEAM - AKBA
40%
Loosely correlated
+8.04%
INZY - AKBA
39%
Loosely correlated
+6.41%
More